Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

Bristol Myers Squibb’s clinical development program ... of Product Characteristics for Breyanzi is available from the EMA website at www.ema.europa.eu. U.S. FDA-Approved Indications BREYANZI ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2024 ...

Prime Medicine, Inc. faces risks in the gene editing sector despite positive developments, caution advised for retail investors. Click for my PRME stock update.

New heart health biopharmaceutical company Kardigan, which counts among its co-founders the director for Northwestern ...

Topalian receives consulting fees from Bristol Myers Squibb, Dragonfly Therapeutics ... We can only achieve this goal ...

Bristol Myers Squibb thanks the patients and investigators involved in ... Full European Summary of Product Characteristics for Breyanzi is available from the EMA website at www.ema.europa.eu. adult ...

Top stock picks for capital appreciation and outperformance, with a focus on profits, dividends, and long-term viability. Click for more on Capital Appreciation.

PlanetDrugsDirect.com has been providing quality medications to satisfied American patients at heavily discounted prices for over twenty years.